NAD(+) supplementation as a novel approach to cURIng HCC?

Area of Science:

• Hepatocellular carcinoma (HCC) research
• Cancer metabolism
• Molecular oncology

Background:

• Hepatocellular carcinoma (HCC) remains a significant global health challenge.
• Understanding the molecular drivers of HCC is crucial for developing effective therapies.
• Metabolic dysregulation is increasingly recognized as a hallmark of cancer.

Purpose of the Study:

• To investigate the role of unconventional prefoldin RPB5 interactor (URI) in hepatocellular carcinoma (HCC) development.
• To elucidate the molecular mechanisms by which URI influences HCC pathogenesis.
• To explore potential therapeutic strategies targeting metabolic pathways in HCC.

Main Methods:

• Analysis of URI expression in HCC models.
• Investigation of URI's interaction with L-tryptophan metabolism.
• Assessment of nicotinamide adenine dinucleotide (NAD(+)) levels in URI-expressing hepatocytes.
• Evaluation of NAD(+) supplementation as a therapeutic intervention.

Main Results:

• Elevated URI expression in hepatocytes promotes HCC development.
• URI interacts with and disrupts L-tryptophan/kynurenine metabolism.
• URI expression leads to altered nicotinamide adenine dinucleotide (NAD(+)) levels.
• NAD(+) supplementation demonstrates potential prophylactic and therapeutic effects in HCC models.

Conclusions:

• URI is a novel oncogenic driver in hepatocellular carcinoma (HCC) linked to metabolic reprogramming.
• Targeting the L-tryptophan/kynurenine/NAD(+) axis presents a promising therapeutic avenue for HCC.
• Nicotinamide adenine dinucleotide (NAD(+)) supplementation warrants further investigation for HCC treatment and prevention.